Reported 23 days ago
Bernstein has maintained a Buy rating on Agilon Health, Inc. (NYSE:AGL), setting a price target of $7.50. The company reported significant growth in fiscal Q1 2025, with total revenues of $1.53 billion and a Medicare Advantage membership of 491,000. Agilon Health is focusing on strategic investments to enhance long-term growth and shareholder value, despite some analysts suggesting greater upside potential in certain AI stocks.
Source: YAHOO